Quantitative assay value distribution between the study groups.
| Anti-CCP2, U Mean ± SD Median (range) | Anti-CCP3, U Mean ± SD Median (range) | AxSYM anti-CCP, U/ml Mean ± SD Median (range) | Anti-MCV, U/ml Mean ± SD Median (range) | RF, IU/ml Mean ± SD Median (range) | |
|---|---|---|---|---|---|
| RA group (n = 93) | 82.3 ± 79 | 150.6 ± 128 | 159.6 ± 392 | 224.1 ± 338 | 144.9 ± 243 |
| 38.7 (1.1–203) | 183.6 (4.8–309) | 18.7 (0.6–3476) | 11.5 (1–1342) | 50.3 (10–1160) | |
| pSS group (n = 17) | 5.6 ± 2.3 | 7.8 ± 3.4 | 7.3 ± 6.8 | 8.3 ± 21 | 20.3 ± 21 |
| 5.4 (1.8–9.9) | 6.6 (4.8–19) | 3.8 (2.1–27.5) | 1 (1–70) | 10 (10–85.3) | |
| SLE group (n = 38) | 6.6 ± 5.2 | 13.3 ± 40 | 4.2 ± 4.3 | 26.1 ± 88 | 10.4 ± 2.3 |
| 4.4 (1.4–23) | 6.2 (3.6–252) | 3.1 (1.3–25.3) | 1 (1–453) | 10 (10–24.3) | |
| OA group (n = 11) | 6.9 ± 4.6 | 6.6 ± 3.6 | 2.4 ± 0.9 | < 1 | 10.6 ± 2.1 |
| 5.2 (1.8–16) | 5.9 (3.7–17) | 2.6 (1.1–3.9) | < 1 | 10 (10–17.1) | |
| HC group (n = 17) | 7.5 ± 5 | 7.7 ± 5.3 | 4.1 ± 2 | < 1 | 10.3 ± 1.4 |
| 5.2 (1.8–17) | 6.4 (3.7–27) | 3.8 (1.9–10.9) | < 1 | 10 (10–15.8) |
SD: standard deviation; RA: rheumatoid arthritis; pSS: primary Sjögren’s syndrome; SLE: systemic lupus erythematosus; OA: osteoarthritis; HC: healthy controls.